Thalidomide and its derivatives are powerful cancer therapeutics that are among the best-
understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 …

The development of bioactive small molecules as probes or drug candidates requires
discovery platforms that enable access to chemical diversity and can quickly reveal new …

Targeted protein degradation is a novel pharmacology established by drugs that recruit
target proteins to E3 ubiquitin ligases. Based on the structure of the degrader and the target …

Over the past 3 years, the first bivalent protein degraders intentionally designed for targeted
protein degradation (TPD) have advanced to clinical trials, with an initial focus on …

Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit
from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to …

Targeted protein degradation (TPD) relies on small molecules to recruit proteins to E3
ligases to induce their ubiquitylation and degradation by the proteasome. Only a few of the …

The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality
with the promise to tame disease-relevant proteins in ways that are difficult or impossible to …

The field of targeted protein degradation is growing exponentially. Yet, there is an unmet
need for pharmacokinetic/pharmacodynamic models that provide mechanistic insights, while …

Imbalances in protein and noncoding RNA levels in vivo lead to the occurrence of many
diseases. In addition to the use of small molecule inhibitors and agonists to restore these …

Proteolysis targeting chimeras (PROTAC) are an emerging precision medicine strategy,
which targets key proteins for proteolytic degradation to ultimately induce cancer cell killing …